UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt

A securities class action contends Unicycive Therapeutics promised shareholders an FDA decision on June 29, 2026 and a commercial launch of oxylanthanum carbonate "later this year," while allegedly never inspecting the third-party manufacturing facility that had already triggered one Complete Response Letter. NEW YORK, Oct. 29, 2026 /PRNewswire/ -- SueWallSt notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026.

PRNewsWire • 10 hours ago

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/2/2026

GlobeNewsWire • 10 hours ago

Kaplan Fox Alerts Investors: Lead Plaintiff Deadline for Unicycive Therapeutics, Inc. (UNCY) is November 2, 2026

New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us.

Newsfile Corp • an hour ago

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection. NEW YORK, Oct. 28, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a securities class action naming Chief Executive Officer Shalabh Gupta and Chief Financial Officer John Townsend as individual defendants has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026.

PRNewsWire • Oct 28, 2026

UNCY DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY

New York, New York--(Newsfile Corp. - October 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • Oct 28, 2026

UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 28, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Newsfile Corp • Oct 28, 2026

DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), Papa John's International, Inc. (PZZA), and FuelCell Energy, Inc. (FCEL): The Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., Papa John's International, Inc., and FuelCell Energy, Inc. Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., Papa John's International, Inc., and FuelCell Energy, Inc.

GlobeNewsWire • Oct 28, 2026

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics, Inc. Securities Lawsuit - Contact Portnoy Law Firm

LOS ANGELES, Oct. 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a securities class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Unicycive common stock between December 29, 2025 and June 29, 2026, inclusive (the 'Class Period'). Find out if you qualify to recover your per-share losses by choosing to join the class action and submit your trade details.

GlobeNewsWire • Oct 27, 2026

UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact SueWallSt

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- SueWallSt alerts investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a securities class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Find out if you may qualify to recover losses.

GlobeNewsWire • Oct 27, 2026

UNCY DEADLINE NOTICE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.

GlobeNewsWire • Oct 27, 2026